Poster Presentations 2023

All the posters and presentations given in the Poster Hall at AMMF’s Virtual European
can be seen here. Please note: This area is intended for HCPs only.

1. Ainhoa Lapitz, Biodonostia Health Research Institute

Liquid biopsy-based protein biomarkers for risk prediction, early diagnosis and prognostication of cholangiocarcinoma

To view the poster, click here.

2. Paula Olaizola, Biodonostia Health Research Institute

Therapeutic potential of targeting protein hyper-SUMOylation in cholangiocarcinoma

To view the poster, click here.

3. Aloña Agirre-Lizaso, Biodonostia Health Research Institute

Scavenger receptor MARCO is associated with an immunosuppressive microenvironment and tumor progression in intrahepatic cholangiocarcinoma

To view the poster, click here.

4. Irene Olaizola, Biodonostia Health Research Institute

Novel platinum-based chemotherapeutic agents halt cholangiocarcinoma progression through the induction of inter-strand DNA breaks, preventing DNA repair mechanisms

To view the poster, click here.

5. Sarah Al-Shakhshir, Al-Shakhshir

Survival outcomes in patients undergoing liver transplantation for primary sclerosing cholangitis (PSC) and incidental cholangiocarcinoma

To view the poster, click here.

6. Juan Valle, University of Manchester and The Christie

Immune-mediated adverse event (imAE) incidence, timing and association with efficacy in the Phase 3 TOPAZ-1 study of durvalumab (D) or placebo (PBO) plus gemcitabine and cisplatin (+GC) in advanced biliary tract cancer (BTC)

To view the poster, click here.

7. Juan Valle, University of Manchester and The Christie

Impact of mutation status on efficacy outcomes in TOPAZ-1: A Phase 3 study of durvalumab (D) or placebo (PBO) plus gemcitabine and cisplatin (+GC) in advanced biliary tract cancer (BTC)

To view the poster, click here.

8. Alan MacDonald, The Royal Marsden Hospital

Prolonged clinical benefit with futibatinib in a patient with FGFR2 fusion-positive intrahepatic cholangiocarcinoma previously treated with an ATP-competitive FGFR inhibitor: case report

To view the poster, click here.

9. Teresa Perra, Azienda Ospedaliero Universitaria di Sassari

Current evidence about preoperative evaluation for major hepatic resections in patients with cholangiocarcinoma

To view the poster, click here.

10. John Bridgewater, UCL Cancer Institute London

Brightline-2: MDM2–p53 antagonist BI 907828 in patients with advanced, MDM2-amplified, TP53 wild-type BTC, PDAC or other selected solid tumours

To view the poster, click here.

11. Valerie E Crolley, University College London

The impact of alterations in cancer driver genes and other potentially targetable mutations on progression and overall survival in patients with intrahepatic cholangiocarcinoma (iCCA) treated on the randomised phase III multicentre BILCAP clinical trial

To view the poster, click here.